Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Carcinoma, Renal Cell 29Carcinoma, Hepatocellular 16Prostatic Neoplasms 12Neoplasm Metastasis 11Carcinoma, Non-Small-Cell Lung 9Neoplasms 8Sarcoma 7Osteosarcoma 6Neuroendocrine Tumors 6Brain Neoplasms 6Urinary Bladder Neoplasms 5Kidney Neoplasms 5Carcinoma, Transitional Cell 5Breast Neoplasms 5Sarcoma, Ewing 4Melanoma 4Lung Neoplasms 4Recurrence 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Clear-cell metastatic renal cell carcinoma 3Carcinoid Tumor 3Adrenocortical Carcinoma 3Adenocarcinoma 3Wilms Tumor 2Uterine Cervical Neoplasms 2Urethral Neoplasms 2Thyroid Neoplasms 2Thyroid Diseases 2Thyroid Cancer, Papillary 2

Interventions

Temozolomide 154Bevacizumab 88Radiotherapy 75Radiation 23Magnetic Resonance Spectroscopy 23Lomustine 18Irinotecan 18pembrolizumab 17Surgical Procedures, Operative 16Carmustine 16Erlotinib Hydrochloride 12Nivolumab 11Specimen Handling 10Aminolevulinic Acid 10sargramostim 9Thalidomide 9Chemotherapy, Adjuvant 9Carboplatin 9Drug Therapy 8Immunoglobulin G 7Filgrastim 7Etoposide 7Disulfides 7Cilengitide 7Sunitinib 6Sorafenib 6O(6)-benzylguanine 6Cyclophosphamide 6antineoplaston AS 2-1 5antineoplaston A10 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Glioblastoma × cabozantinib × Clear all
NCT01068782 2026-02-25

Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

Exelixis

Phase 2 Terminated
19 enrolled 10 charts
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

NCT02885324 2022-10-06

Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children

Indiana University

Phase 2 Terminated
4 enrolled 6 charts
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡